Trebananib: an alternative anti-angiogenic strategy
Mené sur 919 patientes atteintes d'un cancer récidivant de l'épithélium ovarien, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du trebananib, un agent anti-angiogénique, au paclitaxel
Phase 3 clinical trials have shown a significant benefit for anti-angiogenic treatment in ovarian cancer either in the first line or relapsed disease settings. Results of the first-line studies have generally shown a modest progression-free survival benefit, with the exception of AGO-OVAR16 in which a 5·6-month improvement was more impressive, but came at the expense of marked toxic effects. So far, the only study to show a significant overall survival benefit was the ICON6 study, in which...
The Lancet Oncology , commentaire, 2013